Chennai: The Himalaya Drug Company recently shared the results of the clinical study it commissioned to evaluate the role of its herbal products (Tab. Septilin and Tab. Bresol in combination) as an adjuvant treatment in mildly symptomatic and asymptomatic Covid-19–positive patients.

A press release said, the clinical trial was conducted under the supervision of Dr CR Jayanthi, Dean and Director of the prestigious Victoria Hospital (BMCRI – Bangalore Medical College and Research Institute), Bengaluru.

Septilin is a well-known proprietary Ayurvedic formulation with time-tested ingredients such as Guggulu, Yashtimadhu, and Guduchi, and possesses strong immunomodulatory property.

Septilin is also backed by a meta-analysis study and has been recommended by doctors extensively for the past 60 years.

Bresol is a respiratory wellness product with well-known Ayurvedic ingredients such as Haridra, Tulasi, and Vasaka, and is recommended in the management of various respiratory conditions.

Bresol exhibits a potent anti-inflammatory effect because of its ability to down-regulate proinflammatory cytokines.

These products adhere to stringent quality parameters, which makes them ideal to be tested against Covid-19 without any concern whatsoever.

The role of an immunomodulator and a respiratory wellness support in combination (Tab. Septilin + Tab. Bresol) was evaluated as an adjuvant therapy in a group of patients (group 1)who received standard of care (SOC) against another group that received only standard of care (group 2).

Dr Jayanthi said, “Patients treated with Septilin and Bresol along with SOC demonstrated a better trend of reduction of inflammatory cytokines (specially interleukin-6, lactate dehydrogenase, and neutrophil–lymphocyte ratio)as compared with patients who received SOC alone. This clinical trial has demonstrated that adding Septilin and Bresol as adjuvants may have additional long-term benefits in reducing inflammation and may prevent further injury and associated complications.”